Radiopharm Theranostics Completes Dosing of Final Patient in Phase 2B Imaging Trial in Recurrent Brain Metastases from Solid Tumors
MT Newswires Live
Apr 16
Radiopharm Theranostics (ASX:RAD) completed the dosing of the final patient in the US phase 2b imaging trial evaluating the diagnostic performance of fluorine-18-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins, according to a Thursday Australian bourse filing.
The primary objective of the study is concordance between fluorine-18-RAD101 positive lesions and those seen in conventional imaging, magnetic resonance imaging with gadolinium, in participants with suspected recurrent brain metastases.
RAD 101 is a novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.